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Abstract
Background: With more than 940,000 new colorectal cancer cases worldwide each year, there is no better way for
colorectal cancer routine screening. The aim of this study was to investigate whether the fatty acid binding to
albumin is detectably and significantly altered in colorectal cancer patients when compared with healthy people, in
order to find a better way for colorectal cancer diagnosis.
Methods: One hundred and forty-one patients operatively treated for colorectal cancer were included in the
examination, and 180 healthy people were also enrolled as controls. Commercial 16-doxyl stearic acid was used as
spin probe. Serum albumin was analyzed by electron paramagnetic resonance (EPR) with spin probe. Discriminant
analysis was carried out using the measured EPR spectra by SPSS 20.0.
Results: Of the original grouped cases, 89.4% were correctly classified. Of the cross-validated grouped cases, 86.9%
were correctly classified. Using Fisher linear discriminant analysis we were able to develop a mathematical model
allowing for identification of colorectal cancer patients based on five values (both relative intensity and peak width)
which are obtained from the EPR spectrum.
Conclusions: Cancer-associated alterations to albumin can be assessed by spin-label EPR. The potential applications
for this diagnostic technique are significant and represent a cost-effective means for screening patients with cancer.
Spin probe for diagnosis of colorectal cancer might be a useful tool and further studies should take place in order
to investigate all stages of colorectal cancer patients.






Colorectal cancer is the second most common cancer
and the second most common cause of death by cancer
[1]. The clinical stage of the disease at diagnosis often
determines the prognosis and survival rate of a patient
with colorectal cancer [2]. If the colorectal cancer pa-
tient could be diagnosed at an early stage, they will have
a better treatment than if diagnosed at an advanced
stage. However, insufficient evidence concerning prog-
nostic and predictive value exists for other molecular
factors such as thymidylate synthase, microsatellite in-
stability (MSI), p-53 and K-ras. [3].
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reproduction in any medium, provided the orHuman serum albumin (HSA) is the main component
for transport of a variety of peptides and of water-
insoluble fatty acids (FA) in the serum [4]. Its remark-
able ability for binding FA has motivated our group to
use spin-labeled derivatives of stearic acids to monitor
conformational changes around its binding sites [5].
Seven long-chain FA binding sites have been described
so far [6]. Proteins released from tumor cells are able to
bind to albumin and thus lead to a modification of its
structure and function [6,7]. As a consequence, the bind-
ing and transport capacities for FA are also changed.
These changes can be detected by electron paramagnetic
resonance (EPR)/electron spin resonance spectroscopy
[8,9]. EPR is suitable for the determination of functional
characteristics of plasma proteins [7,10]. EPR spectros-
copy detects radicals that are, in the case of HSA,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 The spectrometer operating conditions adopted
during the experiment
Central field 3515 G
Sweep width 150 G
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stable radical (doxyl) chemically attached and by analyz-
ing how these spin-labeled FA bind to albumin [7]. Use
of this technique with 16-doxyl stearic acid (2-(14-
carboxytetradecyl)-2-ethyl-4, 4-dimethyl-3-oxazolidinyloxy)
as spin probe has previously demonstrated cancer-specific
alterations in albumin conformation [10,11]. We used EPR
spectroscopy to investigate the diagnostic utility of serum
albumin conformation analysis in patients with colorectal
cancer and chronic disease.
Methods
Samples
All patients who presented to department of surgical on-
cology PLA People's Liberation Army General Hospital
had been pathologically diagnosed with colorectal cancer
during the study period. Samples were collected from
141 patients with colorectal cancer and 180 blood do-
nors and other volunteers known to be in good health.
All patients provided their consent for participation in
the study (approved by Institute of Radiation Medicine
Chinese Academic of Medical Sciences ethics commit-
tee). Table 1 shows the detailed information. Blood was
obtained by standard venipuncture techniques and col-
lected without any additive. After clotting, serum was
separated by centrifugation for 10 minutes, isolated, and
then stored at −20 °C before analysis.
Sample preparation
Commercial 16-doxyl stearic acid (Sigma-Aldrich GmbH,
Munich, Germany) was used as spin probe. This com-
pound was chosen because of the extremely high binding
constant of albumin for stearic acid (6.9 × 107 L/mol),
generally leading to 99.9% binding of this spin probe to al-
bumin. Here we used a defined concentration of spin
probe-pure ethanol compounds to perform the experi-
ment. Each aliquot received a defined concentration of
spin probe-pure ethanol compounds with 50 μL of serum
and then transformed to a microliter shaker for 10 minutes
at 25°C covered by parafilm. The aliquots were then trans-
ferred into capillary glass tubes for analysis within the EPR
spectrometer. Each sample was measured three times.
Sample measurement
We measured the EPR spectra of each sample with a




TETable 1 Demographic information for patients evaluated
in the study
Group Median age (years) Age range Female (%)
I 72 40-92 62
II 53 27-87 46
Group I, patients with colorectal cancer just after operation (n = 141); Group II,
healthy volunteers (n = 180).A300, Ettlingen, Germany). The spectrometer operating
conditions adopted during the experiments are given in
Table 2.
As the EPR spectrum is comprised of 1024 data
points, we just used Matlab (version 7.0 Math Works
Natick, Massachusetts, U.S.A.) to make up a small pro-
gram to simulate the spectrum curve using least-square
fitting and calculated the peak width and the relative
intensity.Statistical analysis
Gammerman and colleagues [12] and de Noo and col-
leagues [13] described a double cross-validatory implemen-
tation of linear discriminant analysis for the calibration of
a diagnostic rule based on a single spectrum per patient
(and for a single fractionation). Due to non-normal distri-
bution of the raw data, a logarithmic transformation was
needed. To permit comparisons with other studies, results
are presented as means with the standard deviation
obtained after the Ln transformation. Comparisons or cor-
relations were evaluated by using non-parametric tests
(Kruskall Wallis one-way variance analysis or Spearman
Rank test, respectively) on the raw data, and by means of
Student’s t test on normalized data. Discriminant analysis
was carried out using the measured EPR spectra by SPSS
20.0 (IBM, Armonk, New York, U.S.A). Selected values
for variables such as relative intensity and peak widths can
then be used to estimate the biophysical characteristics of
the 16-doxyl stearic acid spin label. The selected parame-
ters are shown in Figure 1. The analysis was performed
using the option of the 'equal prior probability' to assign
the subjects to groups.
All the predictor variables were subjected to stepwise
discriminant function analysis, which has the potential
to optimally separate the two groups; furthermore, the
statistical significance was assessed using Wilks’ lambda.
The variables having the higher discriminant function
coefficient were included in the discriminant function





EMicrowave frequency 9.864 GHz
Microwave power 15.94 MW
Modulation frequency 100 KHz
Modulation amplitude 10 G
Receiver gain 20
Sweep time 20 s
Time constant 0.16 ms









1 0.200 509.437 5 0.002
Figure 1 Selected values in a typical spectrum. ΔH1ΔH2ΔH3
show the relative intensity; ΔH4ΔH5 show the relative peak widths.
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Where F is the discriminant function score, di is the
discriminant function coefficient, V is the score of the
predictor variable and C is the discriminant function
constant.
Results
As shown in Table 3, the five selected values (shown in
Figure 1) were statistically different between the two
groups. The P values of the five parameters were all less
than 0.001, which means they are significantly different
between groups. Linear discriminant analysis was used
based on the five selected parameters.
Table 4 shows the accuracy of the discriminant func-
tion coefficient for all the predictor variables which were
included in the study, from which the highest accurate
values were included for the generation of discriminant
function. The discriminant analysis produced the best
CT
ETable 3 Medians and standard deviation of the variables
analyzed and means and standard deviations of
Ln-transformed levels of selected values
a) ΔH1 ΔH2 ΔH3 ΔH4 ΔH5
Group I Median 118244 122952 56825 15.3 15.378
(n = 141) SD 24751 14729 25265 0.078 0.114
Group II Median 64398 71980 43411 15.192 15.362
(n = 180) SD 11498 12072 6379 0.051 0.086
P value <0.001 <0.001 <0.001 <0.001 <0.001
b) LnΔH1 LnΔH2 LnΔH3 LnΔH4 LnΔH5
Group I Median 11.657 11.697 10.913 2.728 2.73
(n = 141) SD 0.223 0.219 0.266 0.007 0.005
Group II Median 11.17 11.056 10.668 2.721 2.732
(n = 180) SD 0.17 0.186 0.149 0.003 0.006
P value <0.001 <0.001 <0.001 <0.001 <0.001
Group I, patients with chronic disease just after operation (n = 142); Group II,
healthy volunteers (n = 180); SD standard deviation.
a) is the original data.
b) is the data after Ln-transformation. Ln is Logarithmic transformation. ΔH1 is
changed into LnΔH1 after Ln Logarithmic transformation.
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Adiscriminant functions and the predictor variables in-
cluded in the functions were ΔH1ΔH2ΔH3ΔH4 and
ΔH5 based on the greatest univariate discriminant coef-
ficient. Before the formula was calculated with the
greatest univariate discriminant coefficient, they were
subjected to a test of significance using Wilks’ lambda. It
was found the entire assigned predictor variables showed
statistical significance at P < 0.05 (Table 4).
The Fisher’s discriminant functions were as follows:
F1 ¼ 338:904ΔH1þ 88328:145ΔH2−103:109ΔH3
þ 96423:334ΔH4þ 265:178ΔH5−255051:924
F2 ¼ 328:375ΔH1þ 88226:653ΔH2−116:781ΔH3
þ 96324:452ΔH4þ 259:369ΔH5−254166:845
The value obtained using discriminant function for
cancer patients and healthy people is calculated, respect-
ively. This shows that this discriminant function formula
can accurately identify cancer in this population. To ac-
cess whether it is possible to generate accurate cancer
diagnosis models from data collected for this study, dis-
criminant functions were calculated and tested using
cross-validation. This was performed using SPSS, and
the leave-one-out method was chosen to calculate the
cross-validation error rate (Table 5). The discriminant
function used in the present study describes the optimal





ETable 5 Classification accuracy checked using cross-






Original Count 1 128 13 141
2 21 159 180
% 1 90.8 9.2 100.0
2 11.7 88.3 100.0
Cross-validatedc Count 1 124 17 141
2 25 155 180
% 1 87.9 12.1 100.0
2 13.9 86.1 100.0
a89.4% of original grouped cases were correctly classified; b86.9% of cross-
validated grouped cases correctly classified; ccross-validation is done only for
those cases in the analysis. In cross-validation, each case is classified by the
functions derived from all cases other than that case.
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tween them. This is substantiated by the classification
accuracy of functions provided in Table 5. Hence, the
original grouped cases correctly classified were 89.4%.
Discussion
Albumin is the single most abundant protein in non-
pathogenic plasma, comprising approximately two-thirds
of total plasma proteins [4,9,11]. This study shows that
the ability of albumin to bind FA is significantly altered
in patients with colorectal cancer. This modification is
likely caused by the presence of bioactive peptides and
other substances from tumor tissue [5,12,14]. The shape
of the EPR spectrum reflects the state of the spin probe
molecules, such as characteristics of its molecular mo-
tion and electrical and magnetic fields in the surround-
ing environment [11,15,16]. Results of recent application
of EPR spectroscopy in animal models and humans sug-
gest that EPR has great diagnostic potential [9-11].
Discriminant functions have become a widely used
method for disease discrimination [12]. Stepwise dis-
criminant function analysis was applied which calculates
the optimum combination of variables for discriminant
function and weighs them to reflect their contribution to
the determination [12,13]. A deficiency of the current
study was the significant difference in physical conditions
between healthy individuals and patients with colorectal
cancer. Postoperative patients only represent part of the
patients with colorectal cancer. The effect of chemother-
apy, which might have significant influence on tumor-
related metabolite binding to albumin [15,17], as well as
EPR spectral differences caused by tumor stage and
localization [18,19], have not been analyzed here. Automa-
tion of the pipetting and dilution steps would also prob-
ably enhance the precision of the procedure [11].
Conclusions
The obtained results show that cancer-associated alter-
ations to albumin can be assessed by spin-label EPR
[9,11]. Using Fisher linear discriminant analysis we were
able to develop a mathematical model allowing for iden-
tification of colorectal cancer patients with an 89.4%
success rate based on fives values (of both relative inten-
sity and peak width) which are obtained from the EPR
spectrum. The potential applications for this diagnostic
technique are significant and represent a cost-effective
means for screening patients with cancer [11,19]. Fur-
ther studies should take place in order to investigate all
stages of colorectal cancer patients.
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